He Rongke takes ownership of Singapore's SAM Company, becoming a springboard to enter the Southeast Asian cancer treatment market
Through its subsidiary, it invested in SAM Holdings, a listed company in Singapore, with a total investment amount of approximately NT$1.38 billion, holding approximately 50.09% of the shares and gaining control.
Quick Look
- Heronco, a domestic supplier of boron neutron capture therapy, announced that its subsidiary will spend approximately NT$1.38 billion to subscribe for newly issued ordinary shares of Singapore-listed company SAM Holdings.
- After the transaction is completed, it will hold 50.09% of the equity and gain control, thereby expanding its overseas cancer diagnosis and treatment business.
AI-generated summary
Why It Matters
Heronco is a domestic BNCT overall solution provider. This time, it invested in a Singapore listed company through its subsidiary to expand the precision medicine market.
Herongke management team (file photo)
[Reporter Chen Yongji/Report from Taipei] Heronco, a domestic provider of total solutions for boron neutron capture therapy (BNCT), held a board meeting today (10th) and decided to have its subsidiary invest in Singapore-listed company SAM Holdings (SGX: 9G2) and subscribe for SAM at a price of SGD 0.031 per share (equivalent to approximately NT$0.8). Holdings newly issued 1.73 billion ordinary shares, with a total investment amount of SGD 53.63 million (approximately NT$1.38 billion). After the transaction is completed, Herongke will hold approximately 50.09% of SAM Holdings through its subsidiaries and gain control.
Herongke stated that this investment is mainly to introduce high-end medical technology resources, integrate radiological diagnosis, nuclear medicine, targeted nuclear seed therapy, particle therapy, and Herong Technology’s core technology BNCT to create a precision medical service system covering diagnosis to treatment, and accelerate the development of advanced cancer diagnosis and treatment technology.
He Rongke pointed out that SAM Holdings is a Singapore-listed company that is committed to introducing cutting-edge medical technology and integrating clinical expert teams and innovative scientific research resources. Its business scope covers precise cancer diagnosis, integrated diagnosis and treatment (Theragnostics), health examinations, medical cosmetology, proton therapy, photon radiotherapy and comprehensive oncology medical services, etc., and has the most advanced proton therapy center in Southeast Asia.
Through this strategic investment, the two parties will combine Heronco's exclusive technology and industrial resources in the field of BNCT, as well as SAM Holdings' existing proton and photon radiotherapy, cancer diagnosis and oncology medical service capabilities, to jointly build an integrated high-end medical platform covering multiple advanced cancer therapies.
He Rongke emphasized that Singapore has a mature and sound medical system and a high degree of internationalization, and is a key hub connecting Southeast Asia and the global medical market. After obtaining control of SAM Holdings, Herongke will make full use of SAM Holdings' existing medical service foundation and regional market practical experience to expand its overseas business territory and develop the international medical market.
Open Questions
- When is the transaction expected to be officially completed?
